



IN THE DISTRICT COURT OF DOUGLAS COUNTY, NEBRASKA

CHRIS CONRAD and SALLY CONRAD,)
HUSBAND AND WIFE, and TAYLOR)
BISHOP,)
)
Plaintiffs,)
)
vs.)
)
AMNEAL PHARMACEUTICALS, INC.,)
)
Defendant.)

Case No. CI 21-
COMPLAINT

COMES NOW, Plaintiffs and for their cause of action against Defendant allege and state as follows:

1. Plaintiffs Chris and Sally Conrad (the "Conrads") are residents of Sarpy County, Nebraska.
2. Plaintiff Taylor Bishop ("Bishop") is a resident of Douglas County, Nebraska.
3. Defendant, Amneal Pharmaceuticals, Inc. ("Amneal"), is a Delaware corporation with its principal place of business at 400 Crossing Blvd., Bridgewater, NJ 08807. At all times material to this case, Amneal has been engaged in the manufacturing, sale, and distribution of Metformin HCl ER, USP in the United states and distribution and sale in Nebraska.
4. Venue is proper.
5. The Court has jurisdiction as to all events material hereto.
6. Metformin is an oral medication that is used in the treatment of type-2 diabetes. It is one of the topmost prescribed medications in the United States.

7. On or about November 2018 Bishop was diagnosed with Polycystic ovary syndrome (“PCOS”) by Peggy an APRN with LifeCare Family Medicine in Bellevue, Nebraska. She was prescribed Metformin Extended Release on this date to treat the symptoms of her PCOS.

8. Bishop had her thyroid levels checked prior to starting Metformin as a routine test at her doctor visit, at which time they were normal and not above/below average.

9. Bishop was diagnosed with Thyroid Cancer in July of 2019, when she discontinued use of Metformin.

10. There are 11 manufacturers and 6 name brands of Metformin on the market.

11. As of July 13, 2020, several batches of metformin made by different drug manufacturers tested positive for a potential carcinogen. This carcinogen was known to cause thyroid cancer.

12. Because of this carcinogen the FDA requested that Metformin be taken off the market by the manufacturers.

13. As of October 5, 2020, the FDA reported that Amneal Pharmaceuticals recalled their Metformin prescriptions whether expired or not.

14. At the time of her diagnosis in July of 2019, Amneal Pharmaceuticals knew, or should have known, about the carcinogen in Metformin.

15. Amneal is required to complete testing on their medications routinely to make sure that there are no possibly harmful effects or ingredients in them.

16. Amneal has been the subject of multiple FDA investigations into their manufacturing practices and history of ongoing violations with their medications.

17. In one of the most recent inspections done by the FDA of Amneal they were cited for not reviewing the testing data obtained on their manufactured medications.

18. Amneal's Metformin is accompanied by and FDA approved label which gives the consumer the false idea that it is safe and approved by the FDA and that the testing done meets the standards set by the FDA, are safe for consumption, and are without the harmful carcinogens present in the Metformin.

19. Bishop's thyroid levels were normal prior to taking the Metformin manufactured by Amneal. There is no history of thyroid cancer in the family and no other indications of the cause of her diagnosis other than the Metformin carcinogen.

20. Bishop had to undergo surgery and treatment in the amount of \$60,000.00 for the thyroid cancer and will continue to undergo treatment in the amount of \$600.00 per year for the rest of her life.

21. Bishop will suffer not having a thyroid for the rest of life and need to take medication to regulate her body's metabolic rate that controls her heart, muscle and digestive functions. Bishop is also now more susceptible to a secondary cancer.

22. Amneal would have known of the carcinogen in their Metformin if they had followed the testing regulations set by the FDA and reviewed the raw data as required. As such they allowed a harmful product to be put on the market for consumers, under the guise that it was safe and approved by the FDA.

23. Bishop would not have agreed to take, and her doctor would not have prescribed her a medication, that they knew was not properly tested under the FDA

standards. Amneal falsely labeled their Metformin to mislead Bishop to take the prescription which led to her thyroid cancer and injuries.

WHEREFORE, Plaintiffs pray the Court enter an order against Defendant for strict liability for an award of \$2,000,000.00 for past and future medical expenses. Further, Plaintiffs pray for judgment in their favor and against the Defendant for attorney fees and other and further relief as the Court finds just and equitable.

DATED this 29 day of October, 2021.

CHRIS CONRAD and SALLY
CONRAD, and TAYLOR BISHOP,
Plaintiffs,

By: /s/Zachary W. Lutz-Priefert

ZACHARY LUTZ-PRIEFERT, #25902
ALEXANDRIA M. BARTELS #27018
GROSS & WELCH, P.C., L.L.O.
1500 Omaha Tower
2120 South 72nd Street
Omaha, NE 68124
(402) 392-1500
zlutzpriefert@grosswelch.com
abartels@grosswelch.com
Attorneys for Plaintiffs

14270-1/6HT3912

Image ID:
D00762381D01

SUMMONS

Doc. No. 762381

IN THE DISTRICT COURT OF Douglas COUNTY, NEBRASKA
1701 Farnam
Omaha NE 68183

Chris Conrad v. Amneal Pharmaceuticals, Inc.

Case ID: CI 21 10617

TO: Amneal Pharmaceuticals, Inc.

FILED BY
Clerk of the Douglas District Court
10/29/2021

You have been sued by the following plaintiff(s):

Chris Conrad
Taylor Bishop

Sally Conrad

Plaintiff's Attorney: Zachary W Lutz-Priefert
Address: 1500 Omaha Tower
2120 S 72nd St.
Omaha, NE 68124
Telephone: (402) 392-1500

A copy of the complaint/petition is attached. To defend this lawsuit, an appropriate response must be served on the parties and filed with the office of the clerk of the court within 30 days of service of the complaint/petition. If you fail to respond, the court may enter judgment for the relief demanded in the complaint/petition.

Date: OCTOBER 29, 2021

BY THE COURT:

John M. Friend
Clerk



PLAINTIFF'S DIRECTIONS FOR SERVICE OF SUMMONS AND A COPY OF THE COMPLAINT/PETITION ON:

Amneal Pharmaceuticals, Inc.
400 Crossing Blvd.
Bridgewater, NJ 08807

Method of service: Certified Mail

You are directed to make such service within ten days after the date of issue, and file with the court clerk proof of service within ten days after the signed receipt is received or is available electronically, whichever occurs first.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.